AAAAAA

   
Results: 1-10 |
Results: 10
DOPAMINE GENES AND RESPONSE TO CLOZAPINE
Authors: BADRI F MASELLIS M PETRONIS A MACCIARDI FM VANTOL HHM MELTZER HY LIEBERMAN JA POTKIN S KENNEDY JL
Citation: F. Badri et al., DOPAMINE GENES AND RESPONSE TO CLOZAPINE, American journal of medical genetics, 74(6), 1997, pp. 623-623
DIFFERENTIAL LABELING OF DOPAMINE AND SIGMA-SITES BY [H-3] NEMONAPRIDE AND [H-3] RACLOPRIDE IN POSTMORTEM HUMAN BRAINS
Authors: TANG SW HELMESTE DM FANG H LI M VU R BUNNEY W POTKIN S JONES EG
Citation: Sw. Tang et al., DIFFERENTIAL LABELING OF DOPAMINE AND SIGMA-SITES BY [H-3] NEMONAPRIDE AND [H-3] RACLOPRIDE IN POSTMORTEM HUMAN BRAINS, Brain research, 765(1), 1997, pp. 7-12
BRAIN IMAGING TO DETERMINE THE EFFECTS OF SERTINDOLE IN A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN SCHIZOPHRENIC-PATIENTS
Authors: POTKIN S ZBOROWSKI J WU J GILES K BERA R HENRY M SEBREE T AURANG C WALLIN B BUNNEY W
Citation: S. Potkin et al., BRAIN IMAGING TO DETERMINE THE EFFECTS OF SERTINDOLE IN A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN SCHIZOPHRENIC-PATIENTS, Schizophrenia research, 18(2-3), 1996, p.
SDZ MAR-327 - ESTABLISHING AN MTD FOR A PUTATIVE NOVEL ANTIPSYCHOTIC AGENT
Authors: DIAMOND B BORISON R POTKIN S ANAND R HARTMAN R HAPPY J ALPHS L KARSON C KENNEDY B KNESEVICH M MCEVOY J VOLAVKA J
Citation: B. Diamond et al., SDZ MAR-327 - ESTABLISHING AN MTD FOR A PUTATIVE NOVEL ANTIPSYCHOTIC AGENT, Psychopharmacology bulletin, 32(3), 1996, pp. 432-432
NEW DIRECTIONS IN THE PREVENTION AND TREATMENT OF SCHIZOPHRENIA - A BIOLOGICAL PERSPECTIVE
Authors: WYATT RJ APUD JA POTKIN S
Citation: Rj. Wyatt et al., NEW DIRECTIONS IN THE PREVENTION AND TREATMENT OF SCHIZOPHRENIA - A BIOLOGICAL PERSPECTIVE, Psychiatry, 59(4), 1996, pp. 357-370
BRAIN IMAGING TO DETERMINE THE EFFECTS OF SERTINDOLE IN SCHIZOPHRENIC-PATIENTS
Authors: POTKIN S ZBOROWSKI J WU J MACK R BERA R SEBREE T AURANG C BUNNEY W
Citation: S. Potkin et al., BRAIN IMAGING TO DETERMINE THE EFFECTS OF SERTINDOLE IN SCHIZOPHRENIC-PATIENTS, Biological psychiatry, 39(7), 1996, pp. 52-52
A STRUCTURED CLINICAL-ASSESSMENT OF EXTERNAL SENSORY GATING DEFICITS IN SCHIZOPHRENIA
Authors: HETRICK WP YOUSSEF MM JIN Y POTKIN S BUNNEY B SANDMAN C BUNNEY WE
Citation: Wp. Hetrick et al., A STRUCTURED CLINICAL-ASSESSMENT OF EXTERNAL SENSORY GATING DEFICITS IN SCHIZOPHRENIA, Schizophrenia research, 15(1-2), 1995, pp. 177-178
RELIABILITY OF P50 GATING IN NORMAL SUBJECTS
Authors: HETRICK WP OZGUR BM YOUSSEF MM JIN Y POTKIN S SANDMAN CA BUNNEY WE
Citation: Wp. Hetrick et al., RELIABILITY OF P50 GATING IN NORMAL SUBJECTS, Schizophrenia research, 15(1-2), 1995, pp. 178-178
AUDITORY GATING AND COMPONENTS OF THE EEG POWER SPECTRUM IN NORMAL SUBJECTS
Authors: HETRICK WP OZGUR BM JIN Y POTKIN S BUNNEY WE SANDMAN CA
Citation: Wp. Hetrick et al., AUDITORY GATING AND COMPONENTS OF THE EEG POWER SPECTRUM IN NORMAL SUBJECTS, Schizophrenia research, 15(1-2), 1995, pp. 178-178
RELATIONSHIP AMONG CLOZAPINE LEVEL, EEG PHOTIC DRIVING, AND CLINICAL SYMPTOMS
Authors: JIN Y TJAHJONO L CEZAR C MOAYERI S GERBER B POTKIN S
Citation: Y. Jin et al., RELATIONSHIP AMONG CLOZAPINE LEVEL, EEG PHOTIC DRIVING, AND CLINICAL SYMPTOMS, Biological psychiatry, 37(9), 1995, pp. 669-669
Risultati: 1-10 |